2018

Citterio, C (2018) “De novo triiodothyronine (T3) formation in T3 toxicosis of Graves´ Disease (GD)”

  1. E. Citterio, M. Torres, P. Arvan. Fam20C stimulates de novo triiodothyronine (T3) formation within thyroglobulin. Type of Presentation: Poster at the “88th Annual Meeting of the American Thyroid Association (ATA)”. Washington DC, US. Published abstract: Thyroid. October 2018, 28 (S1): A152.

 

Frett, B (2018) “Dual Inhibition of RET and Aurora B to Study the Simultaneous Regulation of Multiple Oncogene Pathways in Medullary Thyroid Cancer”

  1. Naresh, G.; Lakkaniga, N.R.; Kharbanda, A.; Yan, W.; Frett, B.; Li, H. Use of Imidazo[1,2-a]pyridine as a Carbonyl Surrogate in a Mannich-like, Catalyst Free, One-Pot Reaction, Eur. J. Org. Chem. (2019) doi.org/10.1002/ejoc.201801430
  2. Naresh, G.; Kharbanda, A.; Lakkaniga, N.R.; Zhang, L.; Cooper, R.; Li, H.; Frett, B. Catalyst free, C-3 Functionalization of Imidazo[1,2-a]pyridines to Rapidly Access New Chemical Space for Drug Discovery Efforts, ChemComm (2018) DOI: 10.1039/C8CC07063F
  3. Wei, Y.; Lakkaniga, N.R.; Carlomagno, F.; Santoro, M.; McDonald, N.; Lv, F.; Naresh, G.; Frett, B.; Li, H. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application, J Med Chem (2018) DOI: 10.1021/acs.jmedchem.8b01092

2017

Shirley, L (2017) “Impact of BRAF-mutated Papillary Thyroid Cancers on Cancer-Associated Fibroblast Genotype and Phenotype”

  1. Onuma A, Beal EW, Nabhan F, Hughes TM, Farrar WB, Phay JE, Ringel MD, Kloos RT, Shirley LA. “Long-Term Efficacy of Lymph Node Reoperation for Persistent Papillary Thyroid Cancer: 13-Year Follow-up.” Ann Surg Oncol. Accepted.
  2. Squires MH, Jarvis R, Shirley LA, Phay JE. “Intraoperative Parathyroid Autofluorescence Detection in Patients with Primary Hyperparathyroidism.” Ann Surg Oncol. 2019 Jan 23
  3. Rossfeld KK, Saunders N, Tran T, Duh Q, Mansour J, Maithel S, Solorzano C, Wang T, Glenn J, Levine E, Weber S, Salem A, Fields R, Poultsides G, Pawlik T, Phay J, Shirley LA. “The Prognostic Significance of Adrenocortical Carcinomas Identified Incidentally.”  J Surg Oncol. 2018 Dec;118(7):1155-1162.
  4. McDermott S, Saunders N, Schneider E, Onesti J, Davidson G, Bloomston M, Dillhoff M, Schmidt CR, Shirley LA. “Neutrophil lymphocyte ratio and transarterial chemoembolization in neuroendocrine tumor metastases.” J Surg Res. 2018 Dec;232:369-375.
  5. Nguyen MC, Shah MH, Liebner D, Backes FJ, Phay J, Shirley LA. “The Adrenal Gland as a Sanctuary Site of Metastases after Pembrolizumab Treatment: A Case Series.” J Natl Compr Canc Netw. 2018 Nov;16(11):1279-1283.
  6. Strosberg DS, Schneider EB, Onesti J, Saunders N, Davidson G, Konda B, Shah M, Dillhoff M, Schmidt C, Shirley LA. “Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.” Ann Surg Oncol. 2018 Nov;25(12):3613-3620.
  7. Chakedis J, Shirley LA, Terando AM, Skoracki R, Phay JE. Identification of the Thoracic Duct Using Indocyanine Green during Cervical Lymphadenectomy. Ann Surg Oncol. 2018 Nov;25(12):3711-3717.

2016

Min, IM (2016) “Application of chimeric antigen receptor (CAR)-T cell therapy in aggressive thyroid cancer”

  1. Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, Moore MD, Wang W, Park S, Park S, Panjwani S, Gray KD, Tassler AB, Zarnegar R, Fahey TJ 3rd, Jin MM. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors. Clin Cancer Res. 2017 Dec 15;23(24):7569-7583. doi: 10.1158/1078-0432.CCR-17-2008. Epub 2017 Oct 12. PubMed PMID: 29025766; PubMed Central PMCID: PMC5732861.

 

Pozdeyev, N (2016) “Rational combination therapies with lenvatinib for advanced thyroid cancer”

  1. Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. doi: 10.1158/1078-0432.CCR-18-0373. Epub 2018 Apr 3.
  2. Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 Feb 7. doi: 10.1158/1541-7786.MCR-18-1026. [Epub ahead of print]

2015

Lubitz, C (2015) “Clinical utility and cost-effectiveness of a novel blood-based assay for circulating BRAFV600E in patients with papillary thyroid carcinoma”

  1. Lubitz CC, Zhan T, Gunda V, Amin S, Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ, Parangi S. Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma. Thyroid. 2018 Mar;28(3):328-339.
  2. Lubitz CC, Parangi S, Holm TM, Bernasconi J, Schalck AP, Suh H, Economopoulos KP, Gunda V, Donovan SE, Sadow PM, Wirth LJ, Sullivan RJ, and Panka DJ. Detection of circulating BRAFV600E in patients with papillary thyroid carcinoma. J Mol Diagn. 2016 Jan; 18(1):100-108.

 

Nicola, J (2015) “Uncovering Na+/I- Symporter (NIS) interacting proteins: Implications for radioiodide therapy efficiency and diagnosis of radioiodide-avid thyroid tumors”

  1. Martín M, Modenutti CP, Peyret V, Geysels RC, Darrouzet E, Pourcher T, Masini-Repiso AM, Martí MA, Carrasco N, Nicola JP. A Carboxy-Terminal Monoleucine-Based Motif Participates in the Basolateral Targeting of the Na+/I- Symporter.  2019;160(1):156-168.
  2. Martín M, Geysels RC, Peyret V, Bernal Barquero CE, Masini-Repiso AM, Nicola JP. Implications of Na+/I- Symporter Transport to the Plasma Membrane for Thyroid Hormonogenesis and Radioiodide Therapy.  J Endocr Soc. 2018;3(1):222-234

 

Oltmann, S (2015) “Cancer Progression and Therapeutic Response in a Mouse Model of Medullary Thyroid Carcinoma”

  1. Davis JR, Dackiw AP, Holt SA, Nwariaku FE, Oltmann SC. Rapid Relief- Thyroidectomy is a quicker cure than Radioactive Iodine Ablation (RAI) in patients with Hyperthyroidism. World J Surg, 2019, March; 43(3):812-817.
  2. Pozo K, Zahler S, Ishimatus K, Carter AM, Telange R, Wang S, Pfragner R, Fujimoto J, Grubbs EG, Takahashi M, Oltmann SC, Bibb JA. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer. Oncotarget, 2018, Dec 28; 9(102):37662-37675.
  3. Clark A, Rabaglia JL, Dackiw AP, White WD, Nwariaku F, Holt SA, Oltmann SC. Early Endocrine Attending Surgeon Presence Increases Operating Room Efficiency. J Surg Res, 2016; 205(2): 272-8.

Reyna-Neyra, A (2015) “The role of the renal Na+/I- symporter (NIS) in iodide metabolism and thyroid function”

  1. Ferrandino G, Kaspari RR, Reyna-Neyra A, Boutagy NE, Sinusas AJ, Carrasco N. (2017). An extremely high dietary iodide supply forestalls severe hypothyroidism in Na+/I- symporter (NIS) knockout mice. Sci Rep. 7:5329.
  2. Ferrandino G, Kaspari RR, Spadaro O, Reyna-Neyra A, Perry RJ, Cardone R, Kibbey RG, Shulman GI, Dixit VD, Carrasco N. (2017). Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms. Proc Natl Acad Sci U S A. 114: E9172-E9180.

2014

Kim, LA (2014) “Animal Models of Acute and Chronic Thyroid Eye Disease”

  1. Wong LL, Lee NG, Amarnani D, Choi CJ, Bielenberg DR, Freitag SK, D’Amore PA, Kim LA. Orbital Angiogenesis and Lymphangiogenesis in Thyroid Eye Disease: An Analysis of Vascular Growth Factors with Clinical Correlation. Ophthalmology 2016.

 

Untch, B (2014) “Mechanisms of Response and Resistance to Farnesyltransferase Inhibition in HRAS-driven Thyroid Tumors”

  1. Brian R. Untch, Vanessa Dos Anjos, Maria E.R. Garcia-Rendueles, Jeffrey A. Knauf, Gnana P. Krishnamoorthy, Mahesh Saqcena, Umeshkumar K. Bhanot, Nicholas D. Socci, Alan L. Ho, Ronald Ghossein, James A. Fagin. Cancer Res. 2018 Aug 15;78(16):4642-4657. doi: 10.1158/0008-5472.CAN-17-1925. Epub 2018 May 14.

 

Visser, W.E. (2014) “Thyroid Hormone and Aging”

  1. Visser, W.E. Tissue-Specific Suppression of Thyroid Hormone Signaling in Various Mouse Models of Aging. Plos ONE 2016

2013

Bohinc Henderson, B (2013) “Overexpression of LGR4 and LGR5 in Human Thyroid Cancer Promotes Wnt/β-Catenin Signaling and is Associated with Tumor Aggressiveness”

  1. Michelotti G, Jiang X, Sosa JA, Diehl AM, Henderson BB. LGR5 in associated with tumor aggressiveness in papillary thyroid cancer. Oncotarget. 2015 Oct 27;6(33):34549-34560.

 

Morrison, J (2013) “TXNIP as a Regulator of Thyroid Cancer Aggressiveness”

  1. Morrison, JA, et al. 2014. Molecular Cancer. 13: 62. PMID: 24645981

 

Werneck-de-Castro, JP (2013) “What is the role of type II deiodinase (D2)-mediated T3 production in skeletal muscle”

  1. Ignacio DL, Silvestre DH, Anne-Palmer E, Bocco BM, Fonseca TL, Ribeiro MO, Gereben B, Bianco AC, Werneck-de-Castro JP. Early Developmental Disruption of Type 2 Deiodinase Pathway in Mouse Skeletal Muscle Does Not Impair Muscle Function. 2017 Apr;27(4):577-586. doi: 10.1089/thy.2016.0392. Epub 2017 Feb 10.
  2. Bocco BM, Louzada RA, Silvestre DH, Santos MC, Anne-Palmer E, Rangel IF, Abdalla S, Ferreira AC, Ribeiro MO, Gereben B, Carvalho DP, Bianco AC, Werneck-de-Castro JP. Thyroid hormone activation by type 2 deiodinase mediates exercise-induced peroxisome proliferator-activated receptor-γ coactivator-1α expression in skeletal muscle.  J Physiol. 2016 Sep 15;594(18):5255-69. doi: 10.1113/JP272440. Epub 2016 Aug 18.
  3. Werneck-de-Castro JP, Fonseca TL, Ignacio DL, Fernandes GW, Andrade-Feraud CM, Lartey LJ, Ribeiro MB, Ribeiro MO, Gereben B, Bianco AC. Thyroid Hormone Signaling in Male Mouse Skeletal Muscle Is Largely Independent of D2 in Myocytes.  2015 Oct;156(10):3842-52. doi: 10.1210/en.2015-1246. Epub 2015 Jul 27.
  4. Fonseca TL, Werneck-De-Castro JP, Castillo M, Bocco BM, Fernandes GW, McAninch EA, Ignacio DL, Moises CC, Ferreira AR, Gereben B, Bianco AC. Tissue-specific inactivation of type 2 deiodinase reveals multilevel control of fatty acid oxidation by thyroid hormone in the mouse.  2014 May;63(5):1594-604. doi: 10.2337/db13-1768. Epub 2014 Jan 31. Erratum in: Diabetes. 2014 Aug;63(8):2895. Ferreira, Alexandre [corrected to Ferreira, Alexander R].

2012

Wassner, A (2012) “Type 3 Deiodinase in Dilated Heart Failure”

  1. Castroneves LA, Jugo RH, Maynard MA, Lee JS, Wassner AJ, Dorfman D, Bronson RT, Ukomadu C, Agoston AT, Ding L, Luongo C, Guo C, Song H, Demchev V, Lee NY, Feldman HA, Vella KR, Peake RW, Hartigan C, Kellogg MD, Desai A, Salvatore D, Dentice M, Huang SA. Mice with hepatocyte-specific deficiency of type 3 deiodinase have intact liver regeneration and accelerated recovery from nonthyroidal illness after toxin-induced hepatonecrosis. Endocrinology. 2014;155(10):4061-8. PMID: 25004090
  2. Wassner AJ, Jugo RH, Dorfman DM, Padera RF, Maynard MA, Zavacki AM, Jay PY, Huang SA. Myocardial induction of type 3 deiodinase in dilated cardiomyopathy. Thyroid. 2017 May;27(5):732-7. PMID: 28314380

2011

ASTAPOVA, I (2011) “Elucidating the in vivo Mechanisms by Which Thyroid Hormone Regulates Energy Expenditure”

  1. Astapova I. Role of co-regulators in metabolic and transcriptional actions of thyroid hormone. J Mol Endocrinol. 2016 Apr;56(3):73-97. doi: 10.1530/JME-15-0246
  2. Astapova I,Hollenberg AN. The in vivo role of nuclear receptor corepressors in thyroid hormone action. Biochim Biophys Acta. 2013 Jul;1830(7):3876-81. doi: 10.1016/j.bbagen.2012.07.001. Epub 2012 Jul 16. Review.

 

KLUBO-GWIEZDZINSKA, J (2011) “The Role of the Translocator Protein (TSPO) in the Thyroid Cancer Response to the Treatment”

  1. Klubo-Gwiezdzinska J,Jensen K, Bauer A, Patel A, Costello J, BurrrrarrK, Wartofsky L, Hardwick MJ, Vasko VV. The expression of trans locator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress-f-Endocrinol. 2012 May 29.[Epub ahead of print]
  2. Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, Hoperia V, Bauer A, Burman KD, Wartofsky L, Vasko V. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer. 2012 May 24;19(3):447-56.

 

NUCERA, C (2011) “Targeting BRAFV600E with an orally available selective inhibitor in novel in vitro and in vivo preclinical models of human papillary thyroid cancer”

  1. Nucera C, Pontecorvi Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? A.Front Endocrinol (Lausanne). 2012;3:33.
  2. Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, Harris L, Wan L, Fukushima H, Husain A, Nose V, Fadda G, Sadow PM, Goessling W, North T, Lawler J, Wei W. SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med. 2012 Jul 2;209(7):1289-307. Epub 2012 Jun 18.

 

STEFAN, M (2011) “Role of interferon alpha in development of AITD: Epigenetic regulation of key genes.”

  1. Stefan M, Jacobson EM, Huber AK, Greenberg DA, Li CW, Skrabanek L, Conception E, Fadlalla M, Ho K, Tomer Y. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J. Biol. Chem. 286:31168-79, 2011.

2010

BAGHERI-YARMAND, R (2010) “Activating Transcription Factor 4 (ATF4), a novel putative tumor suppressor gene in medullary thyroid cancer”

Publications:

  1. Bagheri-Yarmand R, Sinha KM, Li L, Lu Y, Cote GJ, Sherman SI, Gagel RF. Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Mol Cancer Res. e-Pub 12/2018. PMID: 30552230.
  2. Bagheri-Yarmand R, Williams MD, Grubbs EG, Gagel, RF. ATF4 targets RET for degradation and is a candidate tumor suppressor gene in medullary thyroid cancer. The journal of clinical endocrinology& metabolism 102(3):933-941. e-Pub 3/2017. PMID: 27935748.
  3. Bagheri-Yarmand R, Sinha KM, Gururaj AE, Ahmed Z, Rizvi YQ, Huang SC, Ladbury JE, Bogler O, Williams MD, Cote GJ, Gagel RF. A Novel Dual Kinase Function of the RET Proto-oncogene Negatively Regulates ATF4-Mediated Apoptosis. Journal of Biological Chemistry 290(18):11749-11761, 1/2015. e-Pub . PMCID: PMC25795775.
  4. Bagheri-Yarmand R, Vadlamudi RK, Kumar R. Activating transcription factor 4 overexpression inhibits proliferation and differentiation of mammary epithelium resulting in impaired lactation and accelerated involution. J Biol Chem. 2013 Sep 20;288(38):27517.
  5. Bagheri-Yarmand R, Huang SC, Williams, MD, Cote, GJ, Gagel RF. RET proto-oncogne regulates cell proliferation and apoptosis through repression of ATF4 transcriptional activity in medullary thyroid cancer. Finalist of Cyrus research scholar awards competition. 2011 Research retreat, Division of Internal Medicine, University of Texas, MD Anderson Cancer Center.
  6. Bagheri-Yarmand R,Huang SC, Cote GJ, Gagel RF. Novel mechanism of RET-mediated regulation of cell cycle progression in medullary thyroid cancer. MEN 2010, GUBBIO, Italy, 2010.

Abstracts:

  1. Rozita Bagheri-Yarmand, Krishna M. Sinha, Ling Li, Yue Lu, Robert F. Gagel. Tyrosine kinase and ERAD inhibitors promote oxidative stress-induced apoptosis through activation of ATF4 / KLF9 axis in medullary thyroid cancer. Proceedings of the American Association for Cancer Research Annual Meeting 78 (#2426). e-Pub 2018.
  2. Bagheri-Yarmand R, Sinha K, Li L, Lu Y, Williams DM, Grubbs EG, Cote GJ, Gagel R. Overcoming ATF4 deficiency for treatment of medullary thyroid cancer. 87th Annual Meeting of the American Thyroid Association. e-Pub 2017.
  3. Bagheri-Yarmand R, Sinha K, Lu Y, Gagel R. Tyrosine kinase and ERAD inhibitors synergize to promote apoptosis through ATF4 induction in medullary thyroid cancer. Proceeding AACR 108th Annual Meeting. e-Pub 7/2017.
  4. Bagheri-Yarmand R, Williams MD, Grubbs EG, Gagel RF. ATF4 targets RET for degradation and is a candidate tumor suppressor gene in medullary thyroid cancer. 86th Annual Meeting of the American Thyroid Association, 9/2016.
  5. Bagheri-Yarmand R, Cote GJ, Grubbs EG, Williams MD, Sherman SI, Gagel RF. ATF4 is a putative tumor suppressor gene in medullary thyroid cancer. Proceeding AACR107th Annual meeting. e-Pub 7/2016.
  6. Bagheri-Yarmand R, Gagel RF. Targeting RET and ATF4 pathway to induce apoptosis in MTc. International Thyroid Oncology Group, 5/2016.
  7. Bagheri-Yarmand R, Gilbert J Cote, Robert F Gagel. Nuclear RET Increases Survival by Suppression of ATF4-mediated Apoptosis. 14th world Multiple Endocrine Neoplasia, Vienna, 2014.
  8. Bagheri-Yarmand R, Cote GJ, Gagel RF. Activating Transcription factor 4 regulates RET autophosphorylation and ubiquitin-dependent degradation. Proceeding AACR 105th, San Diego, CA. e-Pub 4/2014.
  9. Bagheri-Yarmand R. Role of RET protooncogene in prevention of apoptosis. American Thyroid Association, 2012.

Book Chapters:

  1. Cote G, Bagheri-Yarmand R, Hofmann MC, Gagel RF. Molecular mechanisms of disease: the RET proto-oncogene. In: Medullary thyroid cancer. Ed(s) D Evans, T Wang. Springer, 47-63, 2016.

 

CORREA-MEDINA, M. (2010) “Deiodinase type 3 is critical for pancreatic islet development and function”

  1. M. Correa-Madina, J. Molina, Y. Gadea, A. Fachado, M. Murillo, G. Simovic, A. Pileggi, A. Hernandez, H. Edlund, and A. C. Bianco. “The Thyroid Hormone-Inactivating Type III Deiodinase Is Expressed in Mouse and Human -Cells and Its Targeted Inactivation Impairs Insulin Secretion.” Endocrinology 152.10 (2011): 3717-727. Print.

 

MITTAG, J (2010) “Regulation of Presympathetic Neuronal Activity by Thyroid Hormone”– 5 citations

  1. Mittag J, Lyons DJ, Sällström J, Vujovic M, Dudazy-Gralla S, Warner A, Wallis K, Alkemade A, Nordström K, Monyer H, Broberger C, Arner A, Vennström B. Thyroid hormone is required for hypothalamic neurons regulating cardiovascular functions. J Clin Invest. 2013 Jan 2;123(1):509-16Epub 2012 Dec 21.

 

PILLI, T (2010) “The role of MADD, an IG20 gene splice variant, and its potential use as therapeutic target in the anaplastic thyroid cancer.”– 2 citations

  1. Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, Christov K, Ganesh L, Maker AV, Li P, Kanteti P, Das Gupta TK, Prabhakar BS. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS One. 2013;8(2):e56817Epub 2013 Feb 15.

2009

FRENCH, JD (2009) “CD4+ T Lymphocyte Polarization in Papillary Thyroid Cancer”

  1. 2. J.D. French, Z.J. Weber, D.L. Fretwell, S. Said, J.P. Klopper, and B.R. Haugen. Tumor-Associated Lymphocytes and Increased FoxP3+ Regulatory T Cell Frequency Correlate with More Aggressive Papillary Thyroid Cancer. Poster presentation at the Inflammation in Oncogenesis Keystone Symposium, Keystone, CO, February 2010.
  2. J.D. French, Z.J. Weber, D.L. Fretwell, M.S. Said, and B.R. Haugen. FoxP3+ Regulatory T Cells are Associated with More Aggressive Papillary Thyroid Cancer. Poster presentation at the American Thyroid Association Conference, Palm Beach, FL, September 2009.

 

MOISE, L (2009) “Induction of Antigen-Specific Tolerance in Autoimmune Thyroiditis”

  1. Moise L, McMurry JA, Buus S, Frey S, Martin WD, De Groot AS. In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine. 2009 Oct 30;27(46):6471-9.

 

WALTER, MA (2009) “Somatostatin-coupled Nanoparticles for Imaging and Therapy of Medullary Thyroid Cancer”

  1. Ng QKT, Segura T, Ben-Shlomo A, Krause T, Mindt TL and Walter MA. Synthesis, Gallium-68 Labeling and Biological Evaluation of DOTA-, NODAGA- and Desferrioxamine-modified Nanoparticles. J Nano Research 2012;20(1):21-31.

2008

KIMURA, HJ (2008) “Macrophage Causes Thyroid Diseases in LMP7 KO Mice: A New Spontaneous Thyroiditis Model”

  1. Iwama S, De Remigis A, Bishop JA, Kimura HJ, Caturegli P. Hürthle cells predict hypothyroidism in interferon-γ transgenic mice of different genetic backgrounds. Endocrinology. 2012 Aug;153(8):4059-66. doi: 10.1210/en.2012-1236. Epub 2012 Jun 19. PMID: 22719056
  2. Xiao Z, Mohamood AS, Uddin S, Gutfreund R, Nakata C, Marshall A, Kimura H, Caturegli P, Womer KL, Huang Y, Jie C, Chakravarti S, Schneck JP, Yagita H, Hamad AR. Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development. Am J Pathol. 2011 Aug;179(2):725-32. doi: 10.1016/j.ajpath.2011.04.016. Epub 2011 Jun 15. PMID: 21718680
  3. Kimura HJ, Suzuki K, Landek-Salgado MA, Caturegli P, Jounai N, Kobiyama K, Takeshita F. Endocr Metab Immune Disord Drug Targets. Application of innate immune molecules for a new class of drugs: infection, inflammation and beyond. 2011 Mar;11(1):68-75. PMID: 21348819
  4. Landek-Salgado MA, Tzou SC, Kimura H, Caturegli P. J Vis Induction of experimental autoimmune hypophysitis in SJL mice. Exp. 2010 Dec 17;(46). doi:pii: 2182. 10.3791/2182. PMID: 21206467
  5. Tzou SC, Landek-Salgado MA, Kimura H, Caturegli P. J Vis Preparation of mouse pituitary immunogen for the induction of experimental autoimmune hypophysitis. Exp. 2010 Dec 17;(46). doi:pii: 2181. 10.3791/2181. PMID: 21206466
  6. Suzuki K, Kimura H, Wu H, Kudo N, Kim WB, Suzuki S, Yoshida A, Caturegli P, Kohn LD. Excess iodide decreases transcription of NIS and VEGF genes in rat FRTL-5 thyroid cells. Biochem Biophys Res Commun. 2010 Mar 5;393(2):286-90. doi: 10.1016/j.bbrc.2010.01.123. Epub 2010 Feb 2. PMID: 20132794
  7. Caturegli P, Kimura H. A nonclassical model of autoimmune hypothyroidism.Thyroid. 2010 Jan;20(1):3-5. doi: 10.1089/thy.2009.1614. PMID: 20067377
  8. Vosters JL, Landek-Salgado MA, Yin H, Swaim WD, Kimura H, Tak PP, Caturegli P, Chiorini JA. Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren’s syndrome. Arthritis Rheum. 2009 Dec;60(12):3633-41. doi: 10.1002/art.24980. PMID: 19950301
  9. Kimura HJ, Chen CY, Tzou SC, Rocchi R, Landek-Salgado MA, Suzuki K, Kimura M, Rose NR, Caturegli P. Immunoproteasome overexpression underlies the pathogenesis of thyroid oncocytes and primary hypothyroidism: studies in humans and mice. PLoS One. 2009 Nov 17;4(11):e7857. doi: 10.1371/journal.pone.0007857.
  10. Landek-Salgado MA, Gutenberg A, Lupi I, Kimura H, Mariotti S, Rose NR, Caturegli P. Pregnancy, postpartum autoimmune thyroiditis, and autoimmune hypophysitis: intimate relationships.Autoimmun Rev. 2010 Jan;9(3):153-7. doi: 10.1016/j.autrev.2009.06.001. Epub 2009 Jun 16.
  11. Gutenberg A, Bell JJ, Lupi I, Tzou SC, Landek-Salgado MA, Kimura H, Su J, Karaviti LP, Salvatori R, Caturegli P. Pituitary and systemic autoimmunity in a case of intrasellar germinoma. Pituitary. 2011 Dec;14(4):388-94. doi: 10.1007/s11102-009-0187-x. Epub 2009 May 26.
  12. Kimura HJ, Rocchi R, Landek-Salgado MA, Suzuki K, Chen CY, Kimura M, Rose NR, Caturegli P. Influence of signal transducer and activator of transcription-1 signaling on thyroid morphology and function. Endocrinology. 2009 Jul;150(7):3409-16. doi: 10.1210/en.2008-1769. Epub 2009 Mar 26.
  13. Chen CY, Kimura H, Landek-Salgado MA, Hagedorn J, Kimura M, Suzuki K, Westra W, Rose NR, Caturegli P. Regenerative potentials of the murine thyroid in experimental autoimmune thyroiditis: role of CD24. Endocrinology. 2009 Jan;150(1):492-9. doi: 10.1210/en.2008-0639. Epub 2008 Sep 18.

 

Leboeuf, R (2008) “Reacquisition of RAI Uptake of RAI-refractory Metastatic BRAF (+) Thyroid Cancers by Pretreatment with the Selective MEK Inhibitor AZD6244”

  1. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. The New England journal of medicine 2013;368:623-32.

 

Schagdarsurengin, U (2008)“Epigenetic Inactivation of Ras Effectors in Thyroid Neoplasm”

  1. Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer. 2010 Sep 29;9:264. doi: 10.1186/1476-4598-9-264.
  2. Schagdarsurengin U, Richter AM, Wöhler C, Dammann RH. Frequent epigenetic inactivation of RASSF10 in thyroid cancer.  2009 Nov 16;4(8):571-6.

2007

Grasberger, H (2007) “Application of Reverse Genetics in the Identification of Defects in the Dual Oxidase Maturation Factor in Humans”

  1. Grasberger H, De Deken X, Mayo OB, Raad H, Weiss M, Liao XH, Refetoff S. Mice deficient in dual oxidase maturation factors are severely hypothyroid. Mol Endocrinol. 2012 Mar;26(3):481-92.
  2. Rigutto S, Hoste C, Grasberger H, Milenkovic M, Communi D, Dumont JE, Corvilain B, Miot F, De Deken X. Activation of dual oxidases Duox1 and Duox2: differential regulation mediated by camp-dependent protein kinase and protein kinase C-dependent phosphorylation. J Biol Chem. 2009 Mar 13;284(11):6725-34.
  3. Zamproni I, Grasberger H, Cortinovis F, Vigone MC, Chiumello G, Mora S, Onigata K, Fugazzola L, Refetoff S, Persani L, Weber G. Biallelic inactivation of the dual oxidase maturation factor 2 (DUOXA2) gene as a novel cause of congenital hypothyroidism. J Clin Endocrinol Metab. 2008 Feb;93(2):605-10.

 

Kim, BW (2007) “Thyroid Hormone, Type 2 Deiodinase, and Energy Expenditure in Human Skeletal Muscle”

  1. McAninch EA, Miller BT, Ueta CB, Jo S, Kim BW Thyroid Hormone and Near Physiologic Concentrations Acutely Increases Oxygen Consumption and Extracellular Acidification in LH86 Hepatoma Ccells. PMID 26287403 Endocrinology 2016 Nov 156(11): 5325-35.

 

SCHWEPPE, RE (2007)  “The Role of FAK and Src Signaling in Thyroid Cancer Cells Resistant to MKK1/2 Inhibition”

  1. Schweppe, RE, Kerege, A, Sharma, V, Poczobutt, JM, Gutierrez-Hartmann, A, Grzywa, RL, and BR Haugen. Distinct Genetic Alterations in the MAPK Pathway Dictate Sensitivity of Thyroid Cancer Cells to MKK1/2 Inhibition. 2009. Thyroid. 19: 825-835 [PMID: 19500021].
  2. Schweppe, RE, French, JD, Kerege, AA, Sharma, V, Grzywa, RL, and BR Haugen. Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase as a Therapeutic Target in Papillary and Anaplastic Thyroid Carcinoma. 2009. J. Clin. Endocrinol. Metab., 94: 2199-2203 [PMID: 19293266].

2006

REDDI, HV.(2006) “Determination of the Oncogenic Potential of PAX8/PPARy Fusion Protein (PPFP) and Elucidation of its Mechanism of Action in Follicular Thyroid Carcinoma”

  1. Reddi HV, Madde P, Milosevic D, Hackbarth JS, Algeciras-Schimnich A, McIver B, Grebe SKG, Eberhardt NL. 2011. The putative PAX8/PPAR fusion oncoprotein exhibits partial tumor suppressor activity through up-regulation of microRNA-122 and dominant negative PPAR activity. Genes & Cancer. 2:46-55.
  2. Reddi HV, Madde P, Marlow L, Copland JA, McIver B, Grebe SKG, Eberhardt NL. 2010. Expression of the PAX8/PPAR fusion protein is associated with decreased neovascularization in vivo: impact on tumorigenesis and disease prognosis. Genes and Cancer. 1:480-492.
  3. Eberhardt NL, Grebe SKG, McIver B and Reddi HV. 2010. The Role of the PAX8/PPAR Fusion Oncogene in the Pathogenesis of Follicular Thyroid Cancer. Mol Cell Endocrinol. 321:50-6. Epub 2009 Oct 31.
  4. Placzkowski KA, Reddi HV, Grebe SKG, Eberhardt NL and McIver B. 2008. The role of the PAX8/PPARgamma fusion oncogene in thyroid cancer. PPAR Res. Vol 2008:672829. Epub 2008 Oct 29.

2005

Heuer, H. (2005) “Generation and Analysis of Mice Deficient in the Thyroid Hormone Transporter MCT8”

  1. Trajkovic-Arsic, M., Müller, J., Darras, V.M. Groba, C., Lee, S., Weih, D., Bauer, K., Visser, T.J., & Heuer (2010) Impact of monocarboxylate transporter (Mct)-8 deficiency on the hypothalamus-pituitary thyroid axis in mice. Endocrinology, 151:5053-5062
  2. Trajkovic-Arsic, M., Visser, T.J., Darras, V.M., Friesema, E.C., Schlott, B. Mittag J., Bauer, K., & Heuer, H. (2010) Consequences of MCT8 deficiency for renal transport and metabolism of thyroid hormones in mice. Endocrinology, 151:802-809.
  3. Heuer, H. & Visser, T.J. (2009) Minireview: Pathophysiological importance of thyroid hormone transporters Endocrinology, 150, 1078-1083
  4. Heuer, H. (2007). The importance of thyroid hormone transporters for brain development and function. Best Practice & Research Clinical Endocrinol Metabol, 21: 265-276.
  5. Trajkovic, M., Visser, T.J., Mittag, J., Horn, S., Lukas, J., Darras, V.M., Raivich, G., Bauer, K., & H. (2007). Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8.  J Clin Invest, 117, 627-635.
  6. Friesema, E.C.H., Jansen, J., Heuer, H., Trajkovic, M., Bauer, K. & Visser, T.J. (2006). Mechanisms of disease: psychomotor retardation and high T3 levels caused by mutations in monocarboxylate transporter 8. Nat Clin Pract Endocrinol Metabol, 2: 512-523

2004

PARANGI, S. (2004) “Antiangiogenic Therapy of Thyroid Cancer”

  1. Nucera C, Porello, A, Antonello ZE, Mekel M Nehs MC, Giordano TJ, Gerald D, Bejamin LE, Priolog C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontercorvi A, Nose V, Lawler J, and Parangi, S :B-RafV600E and Thrombospondin-1 Promote Thyroid Cancer Progression. Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10649-54. Epub 2010 May 24.
  2. Nucera C, Nehs MC, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, and Parangi, S: A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid. 2009 Oct;19(10):1077-84.
  3. Zhang, XF, Xu J, Lawler J, Terwilliger E and Parangi S: Adeno-Associated Virus-Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin.” Clinical Cancer Research 2007 Jul 1; 13(13):3968-76.
  4. Mitchell J. and Parangi, S; “Angiogenesis in Benign and Malignant Thyroid Disease”, Mitchell J. and Parangi, S; “Angiogenesis in Benign and Malignant Thyroid Disease”, Thyroid, Volume 15 (6) 494-510, June 2005

2003

KNAUF, J. (2003) “Tyrosine kinase receptor oncogenes and prostanoid biosynthesis: Role of RET/PTC-induced activation of PGE2 synthase in thyroid tumor genesis”

  1. Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera D, Landa-Lopez I, Knauf JA, Fagin JA, Haugen BR. Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers. Mol Cancer Res. [Epub ahead of print] PMID: 30733375
  2. Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clin Cancer Res. 2019 [Epub ahead of print] PMID: 30737244
  3. Xu B, Reznik E, Tuttle RM, Knauf J, Fagin JA, Katabi N, Dogan S, Aleynick N, Seshan V, Middha S, Enepekides D, Casadei GP, Solaroli E, Tallini G, Ghossein R, Ganly I (accepted) Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features. Endocrine 2019
  4. Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, Wendel HG, Dogan S, Tamarapu PP, Blenis J, Ghossein R, Knauf JA, Rätsch G, Fagin JA. EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC.  Cancer Discov. 2018 [Epub ahead of print] PMID: 30305285.
  5. Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Ni A, Li D, Knauf JA, Pfister DG, Fagin JA, Ho AL. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.  J Clin Endocrinol Metab. 2018 [Epub ahead of print]  PMID: 3025697
  6. Marlow LA, Rohl SD, Miller JL, Knauf JA, Fagin JA, Ryder M, Milosevic D, Netzel BC, Grebe SK, Reddi HV, Smallridge RC, Copland JA. Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.  J Clin Endocrinol Metab. 2018 PMID: 29846633
  7. Knauf JA, Luckett KA, Chen KY, Voza F, Socci ND, Ghossein R, Fagin JA. Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.  J Clin Invest. 2018 [Epub ahead of print].  PMID: 29990309
  8. Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamoorthy GP, Saqcena M, Bhanot UK, Socci ND, Ho AL, Ghossein R, Fagin JA. Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.  Cancer Res. 2018 78(16):4642-4657. PMID: 29760048
  9. Marlow LA, Rohl SD, Miller JL, Knauf JA, Fagin JA, Ryder M, Milosevic D, Netzel BC, Grebe SK, Reddi HV, Smallridge RC, Copland JA. Methodology, criteria and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts.  J Clin Endocrinol Metab. 2018 [Epub ahead of print].  PMID: 29846633
  10. Bellelli R, Vitagliano D, Federico G, Marotta P, Tamburrino A, Salerno P, Paciello O, Papparella S, Knauf JA, Fagin JA, Refetoff S, Troncone G, Santoro M. Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia. Mol Cell Endocrinol. 2018 7207(17): 30350-7. PMID: 28652169
  11. Ibrahimpasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, Deraje S, Carlson DL, Migliacci J, Knauf JA, Untch B, Berger MF, Morris L, Tuttle RM, Chan T, Fagin JA, Ghossein R, Ganly I. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clin Cancer Res. 2017 23(19): 5970-5980. PMID: 28634282
  12. Montero-Conde C, Leandro-Garcia LJ, Chen X, Oler G, Ruiz-Llorente S, Ryder M, Landa I, Sanchez-Vega F, La K, Ghossein RA, Bajorin DF, Knauf JA, Riordan JD, Dupuy AJ, Fagin JA. Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene. Proc Natl Acad Sci U S A. 2017 114(25):E4951-E4960. PMID: 28584132
  13. Azouzi N, Cailloux J, Cazarin JM, Knauf JA, Cracchiolo J, Al Ghuzlan A, Hartl D, Polak M, Carré A, El Mzibri M, Filali-Maltouf A, Al Bouzidi A, Schlumberger M, Fagin JA, Ameziane-El-Hassani R, Dupuy C. NADPH Oxidase NOX4 Is a Critical Mediator of BRAFV600E-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas. Antioxid Redox Signal. 2017 26(15):864-877. PMID: 27401113
  14. Nagarajah J., Le M., Knauf J.A., Ferrandino G., Montero-Conde C., Pillarsetty N., Bolaender A., Irwin C., Krishnamoorthy G.P., Saqcena M. Larson S., Ho A., Seshan V., Nobuya Ishii N., Rosen N., Carrasco N., Weber W., Fagin J. Potent inhibition of ERK output with a MEK inhibitor that prevents reactivation of RAF maximizes the response of BRAF V600E thyroid cancers to radioiodine therapy.  J Clin Invest. 2016 ;126(11):4119-4124 PMID: 27669459
  15. Landa I., Ibrahimpasic T., Boucai L., Sinha R., Knauf J.A., Shah R.H., Dogan S., Ricarte-Filho J.C., Krishnamoorthy G.P., Xu B., Schultz N., Berger M.F., Sander C., Taylor B.S., Ghossein R., Ganly I., Fagin J.A. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126(3):1052-66. PMID: 26878173
  16. Garcia-Rendueles M.E., Ricarte-Filho J.C., Untch B.R., Landa I., Knauf J.A., Voza F., Smith V.E., Ganly I., Taylor B.S., Persaud Y., Oler G., Fang Y., Jhanwar S.C., Viale A., Heguy A., Huberman K.H., Giancotti F., Ghossein R., Fagin J.A. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.  Cancer Discov. 2015 (11):1178-93. PMID: 26359368
  17. Chen X., Makarewicz J.M., Knauf J.A., Johnson L.K., Fagin J.A. Transformation by HrasG12V is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.  2014 33(47):5442-9.  PMID: 24240680
  18. Malaguarnera R., Chen K.Y., Kim T.Y., Dominguez J.M., Voza F., Ouyang B., Vundavalli S.K., Knauf J.A., Fagin J.A. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. J Clin Endocrinol Metab. 2014; 99(10):E1976-87. PMID: 25029414
  19. Ricarte-Filho J.C., Li S., Garcia-Rendueles M.E., Montero-Conde C., Voza F., Knauf J.A., Heguy A., Viale A., Bogdanova T., Thomas G.A., Mason C.E., Fagin J.A. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.  J Clin Invest 2013; 123(11):4935-44.  PMID: 24135138
  20. Gild M.L., Landa I., Ryder M., Ghossein R.A., Knauf J.A., Fagin J.A. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.  Endocr Relat Cancer 2013; 20(5):659-67. PMID: 23828865
  21. Ryder M., Gild M., Hohl T.M., Pamer E., Knauf J., Ghossein R., Joyce J.A., Fagin J.A. Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression. PLoS One 2013; 8(1):e54302. PMID: 23372702
  22. Montero-Conde C., Ruiz-Llorente S., Dominguez J.M., Knauf J.A., Viale A., Sherman E.J., Ryder M., Ghossein R.A., Rosen N., Fagin J.A. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.  Cancer Discov. 2013; 3(5):520-533.  PMID: 23365119
  23. Couto J.P., Daly L., Almeida A., Knauf J.A., Fagin J.A., Sobrinho-Simões M., Lima J., Máximo V., Soares P., Lyden D., Bromberg J.F. STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A. 2012; 109(35):E2361-70. PMID: 22891351
  24. Madsen L.W., Knauf J.A., Gotfredsen C., Pilling A., Sjögren I., Andersen S., Andersen L., de Boer A.S., Manova K., Barlas A., Vundavalli S., Nyborg N.C., Knudsen L.B., Moelck A.M., Fagin J.A. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012; 153(3):1538-47. PMID: 22234463
  25. Chakravarty D., Santos E., Ryder M., Knauf J.A., Liao X.H., West B.L., Bollag .G, Kolesnick R., Thin T.H., Rosen N., Zanzonico P., Larson S.M., Refetoff S., Ghossein R., Fagin J.A. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011; 121:4700-11.  PMID: 22105174
  26. Read M.L., Lewy G.D., Fong J.C.W., Sharma N., Seed R.I., Smith V.E., Gentilin E., Warfield A., Eggo M.C., Knauf J.A., Leadbeater W.E., Watkinson J.C., Franklyn J.A., Boelaert K .and McCabe C.J. “Proto-oncogene PBF/PTTG1IP regulates thyroid growth and represses radioiodide treatment” Cancer Research 2011; 71(19):6153-64. PMID: 21844185
  27. Knauf J.A., Sartor M.A, Medvedovic M., Lundsmith E., Ryder M., Salzano M., Nikiforov Y.E., Giordano T.J., Ghossein R.A., James A Fagin J.A. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling Oncogene 2011; 30(28):3153-62. PMID: 21383698
  28. Franco A.T., Malaguarnera1 R., Refetoff S., Liao X-H., Lundsmith E., Kimura S., Pritchard C., Marais R, Davies, T, Rosen R., Ghossein R., Knauf J.A., Fagin J.A. Thyrotrophin Receptor Signaling-Dependence Of Braf-Induced Thyroid Tumor Initiation In Mice  Proc Natl Acad Sci USA 2011; 108(4):1615-20. PMID: 21220306
  29. Rivera M., Ricarte-Filho J., Tuttle R.M., Ganly I., Shaha A., Knauf J., Fagin J., Ghossein R. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid 2010; 20(10):1085-93.  PMID: 20860430
  30. Rivera M., Ricarte-Filho J., Knauf J., Shaha A., Tuttle M., Fagin J.A., Ghossein R.A. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns Mod Pathol 2010.  PMID: 20526288
  31. Ricarte-Filho J.-C.M., Ryder M., Chitale D.A., Rivera M., Heguy A., Ladanyi M., Janakiraman M., Solit D., Knauf J.A., Tuttle R.M, Ghossein R.A., and Fagin J.A. “Mutational Profile Of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers By Mass Spectrometry Reveals Distinct Roles for BRAF, PIK3CA and AKT1 in Disease Pathogenesis” Cancer Research 2009; 69(11):4885-93.  PMID: 19487299
  32. Chen X., Mitsutake N, LaPerle K., Akeno N., Zanzonico P., Longo V.A., Mitsutake S., Kimura E.T., Geiger H., Santos E., Wendel H.G., Franco A., Knauf J.A., and Fagin J.A. “Endogenous Expression Of HrasG12V Induces Developmental Defects and Neoplasms With Copy Number Imbalances Of The Oncogene”  Proc Natl Acad Sci USA 2009; 106(19):7979-84.  PMID: 19416908
  33. Ryder M, Ghossein R, Ricarte-Filho J, Knauf JA, and Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer Endocr Relat Cancer 2008; 15(4):1069-1074.  PMID: 18719091
  34. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC, Haugen BR. DNA Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting In Cell Line Redundancy and Misidentification J Clin Endocrinol Metab 2008; 93(11):4331-41.  PMID: 18713817
  35. Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.  Cancer Research 2008; 68(11):4183-4191.  PMID: 18519677
  36. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, and Fagin JA. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines J Clin Endocrinol Metab 2008; 93(6):2194-2201. PMID: 18381570
  37. Akeno-Stuart, N, Croyle, M, Knauf, JA, Malaguarnera, R, Vitagliano, D, Santoro, M, Stephan, C, Grosios, K, Wartmann, M, Cozens, R, Caravatti, G, Fabbro, D, Lane, HA, Fagin, JA. The Ret Kinase Inhibitor Nvp-Ast487 Blocks Growth And Calcitonin Gene Expression Through Distinct Mechanisms In Medullary Thyroid Cancer Cells: Implications For Use Of Biomarkers In Targeted Cancer Therapies.  Cancer Research 2007; 67(14):6956-64.  PMID: 17638907
  38. Mesa M Jr.1, Mirza M, Mitsutake N, Sartor MA, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, and Fagin JA. Conditional activation of the RET/PTC3 and BRAFV600E oncoproteins in thyroid cells is associated with unique patterns of gene expression that predict distinct functional properties and a preferential role of BRAF in extracellular matrix remodeling.  Cancer Research 2006; 66(13):6521-6529. PMID: 16818623
  39. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, and Fagin JA. Inhibitors Of RAF Kinase Activity Block Growth Of Thyroid Cancer Cells With RET/PTC Or BRAF Mutations In Vitro And In Vivo.  Clinical Cancer Research 2006; 12(6):1785-1793. PMID: 16551863
  40. Knauf JA, Ouyang B, Knudsen, ES, Fukasawa K, Babcock G, and Fagin, JA. Oncogenic Ras Induces Accelerated Transition Through G2/M And Promotes Defects In The G2 DNA Damage And Mitotic Spindle Checkpoints.  J Biol Chem. 2006; 281(7):3800-3809. PMID: 16316983
  41. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C Jr., Knauf JA, Zhang L, Taira K, and Fagin JA. BRAF Mediates RET/PTC-Induced MAPK Activation In Thyroid Cells: Functional Support For Requirement Of The RET/PTC-RAS-BRAF Pathway In Papillary Thyroid Carcinogenesis Endocrinology 2006; 147(2): 1014-1019. PMID: 16254036
  42. Puxeddu E, Knauf JA, Sartor MA, Mitsutake N, Smith EP, Medvedovic M, Tomlinson CR, Moretti S, and Fagin JA. RET/PTC-Induced Gene Expression in Thyroid PCCL3 Cells Reveals Early Activation Of Genes Involved in Regulation of the Immune Response.  Endocrine Related Cancer 2005; 12(2):319-34. PMID: 15947106
  43. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, and Fagin JA. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.  Cancer Research 2005; 65(10):4238-45.  PMID: 15899815
  44. Ciampi R, Knauf JA, Rabes HM, Fagin JA, and Nikiforov YE. BRAF Kinase Activation Via Chromosomal Rearrangement in Radiation-Induced and Sporadic Thyroid Cancer.  Cell Cycle 2005; 4(4):547-548. PMID: 15753649
  45. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr., Zhang L, and Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.  Cancer Research 2005; 65(6):2465-2473. PMID: 15781663
  46. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, and Nikiforov YE. Oncogenic AKAP9-BRAF Fusion is a Novel Mechanism of MAPK Pathway Activation in Thyroid Cancer.  Journal of Clinical Investigation 2005; 115(1):94-101. PMID: 15630448
  47. Nikiforova, MN, Ciampi, R, Salvatore, G, Santoro, M, Gandhi, M, Knauf, JA, Thomas, GA, Jeremiah, S, Bogdanova, TI, Tronko, MD, Fagin, JA, Nikiforov, YE. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.  Cancer Lett. 2004; 209(1):1-6. PMID: 15145515
  48. Puxeddu E, Mitsutake N, Knauf JA, Moretti S, Kim HW, Seta KA, Brockman D, Myatt L, Millhorn DE, Fagin JA. Microsomal prostaglandin E2 synthase is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.  J Biol Chem. 2003; 278(52):52131-52138. PMID: 14555660
  49. Nikiforova, MN, Kimura, ET, Gandhi, M, Knauf, JA, Basolo, F, Zhu, Z, Giannini, R, Salvatore, G, Fusco, A, Santoro, M, Fagin, JA, and Nikiforov, YE. BRAF Mutations in Thyroid Tumors are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas.  J Clin Endocrinol Metab. 2003; 88(11):5399-5404. PMID: 14602780
  50. Knauf JA, Kimura E, Ouyang B, Croyle ML, and Fagin, JA Acute Expression of RET/PTC Induces Isozyme-Specific Activation and Subsequent Downregulation of PKCε in PCCL3 Thyroid Cells.  Oncogene 2003; 22(44):6830-6838. PMID: 14534528
  51. Knauf, JA, Kuroda, H, Basu, S, and James A Fagin RET/PTC-Induced Dedifferentiation of Thyroid Cells is Mediated Through Y1062 Signaling Through Shc-Ras-Map Kinase.  Oncogene 2003; 22(28):4406-4412. PMID: 12853977
  52. Wang J, Knauf JA, Basu S, Puxeddu E, Kuroda H, Santoro M, Fusco A, and Fagin JA. Conditional Expression of RET/PTC Induces a Weak Oncogenic Drive in Thyroid PCCL3 Cells and Inhibits TSH Action at Multiple Levels.  Endocrinology 2003; 17(7):1425-1436. PMID: 12690093
  53. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, and Fagin JA. High Prevalence of BRaf Mutations in Thyroid Cancer: Genetic Evidence For Constitutive Activation of the RET/PTC-Ras-BRaf Signaling Pathway in Papillary Thyroid Carcinoma.  Cancer Research 2003; 63(7):1454-1457. PMID: 12670889

 

JACOBSON, E. “Molecular determinants of the presentation of immunogenic thyroglobulin peptides by HLA-DR3”

New to the thyroid field; no prior thyroid publications

 

XU, XIULONG* (2003)”BRAF gene mutation and oncogenesis of papillary thyroid carcinomas”

* ThyCa award

  1. Xu X, Quiros RM, Maxhimer JB, Jiang P, Marcinek R, Ain KB, Platt JL, Shen J, Gattuso P, Prinz RA 2003. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res 9:5968-5979.
  2. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA 2003. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567.

2002

A.C. BIANCO (2002)”Type 2 deiodinase-mediated intra-cellular thyrotoxicosis in brown adipocytes is critical for energy homeostasis and adaptive thermogenesis in small mammals”

  1. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439:484-489.
  2. Kalaany NY, Gauthier KC, Zavacki AM, Mammen PP, Kitazume T, Peterson WL, Garry DJ, Bianco AC, Mangelsdorf DJ. LXRs regulate the balance between fat storage and oxidation. Cell Metab 2005; 1:231-44.
  3. Christoffolete MA, Linardi CC, de Jesus L, Ebina KN, Carvalho SD, Ribeiro MO, Rabelo R, Curcio C, Martins L, Kimura ET, Bianco AC 2004. Mice with targeted disruption of the Dio2 gene have cold-induced overexpression of the uncoupling protein 1 gene but fail to increase brown adipose tissue lipogenesis and adaptive thermogenesis. Diabetes
    53:577-584.
  4. Nakayama A, Bianco AC, Zhang CY, Lowell BB, Frangioni JV 2003. Quantitation of brown adipose tissue perfusion in transgenic mice using near-infrared fluorescence imaging. Mol Imaging 2:37-49.
  5. Baqui M, Botero D, Gereben B, Curcio C, Harney JW, Salvatore D, Sorimachi K, Larsen PR, Bianco AC 2003. Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes. J Biol Chem 278:1206-1211.
  6. Curcio-Morelli C, Zavacki AM, Christofollete M, Gereben B, de Freitas BC, Harney JW, Li Z, Wu G, Bianco AC
    2003. Deubiquitination of type 2 iodothyronine deiodinase by von Hippel-Lindau protein-interacting deubiquitinating enzymes regulates thyroid hormone activation. J Clin Invest 112:189-196.
  7. Freitas FR, Moriscot AS, Jorgetti V, Soares AG, Passarelli M, Scanlan TS, Brent GA, Bianco AC, Gouveia CH
    2003. Spared bone mass in rats treated with thyroid hormone receptor TR beta-selective compound GC-1. Am J Physiol Endocrinol Metab 285:E1135-E1141.
  8. Kim BW, Zavacki AM, Curcio-Morelli C, Dentice M, Harney JW, Larsen PR, Bianco AC 2003. Endoplasmic reticulum-associated degradation of the human type 2 iodothyronine deiodinase (D2) is mediated via an association between mammalian UBC7 and the carboxyl region of D2. Mol Endocrinol 17:2603-2612.

 

KOPP, P. (2002) “Targeted overexpression of a dominant negative insulin growth factor I (IGFI) in thyroid cells”

  1. Gillam MP, Sidhaye AR, Lee EJ, Rutishauser J, Stephan CW, Kopp P 2004. Functional characterization of pendrin in a polarized cell system. Evidence for pendrin-mediated apical iodide efflux. J Biol Chem 279:13004-
    13010.
  2. Kopp P 2002. Perspective: genetic defects in the etiology of congenital hypothyroidism. Endocrinology 143:2019-2024.2001

2001

CATUREGLI, P. (2001)”Interleukin-12 and autoimmune thyroiditis”

  1. Caturegli P, Rose NR, Kimura M, Kimura H, Tzou SC 2003. Studies on murine thyroiditis: new insights from organ flow cytometry. Thyroid 13:419-426.
  2. Barin JG, Afanasyeva M, Talor MV, Rose NR, Burek CL, Caturegli P 2003. Thyroid-specific expression of IFN-gamma limits experimental autoimmune thyroiditis by suppressing lymphocyte activation in cervical lymph nodes. J Immunol 170:5523-5529.
  3. Bonita RE, Rose NR, Rasooly L, Caturegli P, Burek CL 2003. Kinetics of mononuclear cell infiltration and cytokine expression in iodine-induced thyroiditis in the NOD-H2h4 mouse. Exp Mol Pathol 74:1-12.
  4. Bonita RE, Rose NR, Rasooly L, Caturegli P, Burek CL 2002. Adhesion molecules as susceptibility factors in spontaneous autoimmune thyroiditis in the NOD-H2h4 mouse. Exp Mol Pathol 73:155-163.

 

PHILIBERT R. (2001) “Role of thyroid hormone and TRAP230 in dopaminergic cell survival and differentiation”– 5 citations

  1. Philibert RA, Sandhu HK, Hutton AM, Wang Z, Arndt S, Andreasen NC, Crowe R, Wassink TH 2001. Population- based association analyses of the HOPA12bp polymorphism for schizophrenia and hypothyroidism. Am J Med Genet. 105:130-134.

2000

LIU, Y-Y. (2000) “Thyroid hormone regulation of neural differentiation”

  1. Yan-Yun Liu, Gregory A. Brent Thyroid hormone and the brain: Mechanisms of action in development and role in protection and promotion of recovery after brain injury Pharmacology & Therapeutics 186 (2018) 176–185.
  2. Liu Y-Y and Brent GA. Posttranslational modification of Thyroid Hormone receptors. In: Thyroid Hormone Nuclear Receptors. Edited by Michhellina Plateroti and Jacques Samarut. Springer publisher. Human press, 2018.
  3. Teng X, Liu YY, Teng W, Brent GA. COUP-TF1 Modulates Thyroid Hormone Action in an Embryonic Stem-Cell Model of Cortical Pyramidal Neuronal Differentiation. Thyroid 2018 May; 28(5):667-678.
  4. Anna Milanesi, Jang-Won Lee, An Yang, Yan-Yun Liu, Sargis Sedrakyan, Sheue- yann Cheng, Laura Perin, and Gregory A. Brent. Thyroid Hormone Receptor Alpha is Essential to Maintain the Satellite Cell Niche during Skeletal Muscle Injury and Sarcopenia of Aging. Thyroid Oct 2017
  5. J Li, I. Donangelo, K. Abe , O. Scremin , S. Ke , F. Li , A. Milanesi , Liu and Gregory A. Brent. (YL and GAB are the co-corresponding author). Thyroid hormone treatment activates protective pathways in both in vivo and in vitro models of neuronal injury. Molecular and Cellular Endocrinology 2017 Sep 5; 452:120-130.
  6. Milanesi A, Lee JW, Kim NH, Liu YY, Yang A, Sedrakyan S, Kahng A, Cervantes V, Tripuraneni N, Cheng SY, Perin L, Brent GA. Thyroid Hormone Receptor α Plays an Essential Role in Male Skeletal Muscle Myoblast Proliferation, Differentiation and Response to Injury. Endocrinology. 2016 Jan; 157(1):4-15.
  7. Jang-Won Lee, Laura Perin , Nam-Ho Kim, Valentina Villani, Vanessa Cervantes, Andrew Kahng, Yan-Yun Liu, Gregory A. Brent and Anna Milanesi PCNA Modulates Beta-cell Apoptosis. American Journal of Physiology Endocrinology and Metabolism. 2016.
  8. Liu YY, Ayers S, Milanesi A, Teng X, Rabi S, Akiba Y, Brent GA. Thyroid hormone receptor sumoylation is required for preadipocyte differentiation and proliferation. J Biol Chem. 2015 Mar 20; 290(12):7402-15. (YL and GAB are the Co-corresponding author.)
  9. Scremin OU, Roch M, Norman KM, Djazayeri S, Liu YY. Brain acetylcholine and choline concentrations and dynamics in a murine model of the fragile X syndrome: age, sex and region-specific changes. Neuroscience. 2015 Aug 20; 301:520-8.
  10. Rashmi Mullur, Yan-Yun Liu, and Gregory A. Brent, Thyroid hormone regulation of metabolism Physiology Review 94: 355-382, 2014.
  11. Liu Y-Y Metabolic signal crosstalk: Thyroid hormone and Liver X receptor Journal of Endocrinology, Diabetes and Obesity 1: 1006, 2013.
  12. Liu Y-Y, Takahiko Kogai, James J. Schultz, Kaizeen Mody, and Gregory A. Brent Thyroid Hormone Receptor Isoform-specific Modification by Small Ubiquitin-like Modifier (SUMO) Modulates Thyroid Hormone-dependent Gene Regulation. J. Biol. Chem. 2012, 287:36499-36508.
  13. Liu Y-Y, Schultz JJ, Kogai T and Brent GA. Thyroid hormone negative regulation of angiogenesis inhibitor Kalikrein-Binding Protein Endocrinology 2011, 152(3):1143–1153.
  14. Kogai T, Liu, Y-Y, Laura Richter L. Kaizeen Mody K, Kagechika H and Brent GA. Retinoic Acid Induces Expression of the Thyroid Hormone Transporter, Mct8, In Mouse Embryonic Cells. J. Biol. Chem. 2010, 285:27279-27288.
  15. Liu Y-Y and Brent GA Thyroid Hormone Crosstalk with Nuclear Receptor Signaling in Metabolic Regulation Trends in Endocrinology and Metabolism 21:166-173 (2009)
  16. Kogai T, Sajid-Crockett S, Newmarch LS, Liu Y-Y and Brent GA. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillar thyoid cnacer cells. Journal of Endocrinology 199: 1-11 (2008)
  17. Liu Y-Y and Brent GA. Stealth sequences in reporter gene vector confound studies of T3-regulated negative expression Thyroid 18(6): 593-595 (2008).
  18. Liu Y-Y, Heymann RS, Moatamed F, Schultz JJ, Sobel D, Brent GA. A mutant thyroid hormone receptor alpha antagonizes peroxisome proliferator-activated receptor alpha signaling in vivo and impairs fatty acid oxidation. Endocrinology 148(3):1206-17 (2007)
  19. Yan Ao, Vay Liang W. Go, Natalie Toy, Tei Li, Yu Wang, Moon K. Song, Joseph R. Reeve, Yan-Yun Liu, and Hong Yang Brainstem Thyrotropin-Releasing Hormone Regulates Food Intake through Vagal-Dependent Cholinergic Stimulation of Ghrelin Secretion. Endocrinology 147(12):6004-10 (2006)
  20. Liu Y-Y and Brent GA Thyroid hormone-dependent gene expression in differentiated embryonic stem cells and embryonal carcinoma cells: identification of novel thyroid hormone target genes by deoxyribonucleic acid microarray analysis. Endocrinology. 146(2):776-83. (2005).
  21. Liu YY, Schultz JJ, Brent GA 2003. A thyroid hormone receptor alpha gene mutation (P398H) is associated with visceral adiposity and impaired catecholamine-stimulated lipolysis in mice. J Biol Chem 278:38913-38920.
  22. Liu YY, Brent GA 2002. A complex deoxyribonucleic acid response element in the rat Ca(2+)/calmodulin- dependent protein kinase IV gene 5′-flanking region mediates thyroid hormone induction and chicken ovalbumin upstream promoter transcription factor 1 repression. Mol Endocrinol 16:2439-2451.
  23. Liu YY, Tachiki KH, Brent GA 2002. A targeted thyroid hormone receptor alpha gene dominant-negative mutation (P398H) selectively impairs gene expression in differentiated embryonic stem cells. Endocrinology
    143:2664-2672.
  24. Liu, Y-Y, Milanise, A. and Brent GA. “Thyroid Hormones” in Hormone Signaling in Biology and Medicine. Edited by Gerry Litwack, published by Elsevier/Academic Press, Oxford, UK).

 

RINGEL, M. (2000) “The role of AKT in thyroid tumorigenesis”

  1. Ringel MD 2004. Molecular detection of thyroid cancer: differentiating “signal” and “noise” in clinical assays. J Clin Endocrinol Metab 89:29-32.
  2. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M
    2001. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61:6105-6111.
  3. Ringel MD, Hardy E, Bernet VJ, Burch HB, Schuppert F, Burman KD, Saji M 2002. Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. J Clin Endocrinol Metab 87:2399
  4. Saito J, Kohn AD, Roth RA, Noguchi Y, Tatsumo I, Hirai A, Suzuki K, Kohn LD, Saji M, Ringel MD 2001. Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 11:339-351.

1999

MARINÒ, M. (1999) “Megalin (gp330) in thyroid physiology and pathology”

  1. Lisi S, Chiovato L, Pinchera A, Marcocci C, Menconi F, Morabito E, Altea MA, McCluskey RT, Marinò M Impaired thyroglobulin (Tg) secretion by FRTL-5 cells transfected with soluble receptor associated protein (RAP): evidence for a role of RAP in the Tg biosynthetic pathway. J Endocrinol Invest 26:1105-1110.? OMIT
  2. Marinò, M, Lisi S, Pinchera A, Chiovato L, McCluskey RT 2003. Targeting of thyroglobulin to transcytosis following megalin-mediated endocytosis: evidence for a preferential pH-independent pathway. J Endocrinol Invest 26:222-229.
  3. Lisi S, Pinchera A, McCluskey RT, Chiovato L, Marinò M. Binding of heparin to human thyroglobulin (Tg) involves multiple binding sites including a region corresponding to a binding site of rat Tg. Eur. J. Endocrinol. 2002. 146: 591-602.
  4. Marinò M, Lisi S, Pinchera A, Mazzi B, Latrofa F, Sellari-Franceschini S, McCluskey RT, Chiovato L. Identification of thyroglobulin in orbital tissues of patients with thyroid associated ophthalmopathy. Thyroid 2001. 11: 177-185.
  5. Marinò M, Andrews D., Brown D., McCluskey R.T. Transcytosis of retinol binding protein across renal proximal tubule cells following megalin (gp330)-mediated endocytosis. J Am Soc Nephr. 2001. 12: 637-648.
  6. Marinò M, Chiovato L, Lisi S, Pinchera A, McCluskey RT. Phosphoinositide 3-kinase (pi3-k) inhibits megalin-mediated transcytosis of thyroglobulin across thyroid epithelial cells at a post-sorting level. Eur J Endocrinol 2001. 145: 477-483.
  7. Marinò M, Pinchera A, McCluskey RT, Chiovato L. Megalin in thyroid physiology and Pathology. Thyroid 2001. 11: 47-56.
  8. Marinò M, McCluskey RT 2000. Role of thyroglobulin endocytic pathways in the control of thyroid hormone release. Am J Physiol Cell Physiol 279:C1295-C1306.
  9. Marinò M, Chiovato L, Mitsiades N, Latrofa F, Andrews D, Tseleni-Balafouta S, Collins AB, Pinchera A, McCluskey RT 2000. Circulating thyroglobulin transcytosed by thyroid cells in complexed with secretory components of its endocytic receptor megalin. J Clin Endocrinol Metab 85:3458-3467.
  10. Marinò M, McCluskey RT 2000. Megalin-mediated transcytosis of thyroglobulin by thyroid cells is a calmodulin-dependent process. Thyroid 10:461-469.
  11. Marinò M, Zheng G, Chiovato L, Pinchera A, Brown D, Andrews D, McCluskey RT 2000. Role of megalin (gp330) in transcytosis of thyroglobulin by thyroid cells. A novel function in the control of thyroid hormone release. J Biol Chem 275:7125-7137.

 

ZAVACHI, A.M. (1999) “Regulation of thyroid hormone responsive genes by the nuclear receptor RIP 14”

  1. Kim BW, Zavacki AM, Curcio-Morelli C, Dentice M, Harney JW, Larsen PR, Bianco AC 2003. Endoplasmic reticulum-associated degradation of the human type 2 iodothyronine deiodinase (D2) is mediated via an association between mammalian UBC7 and the carboxyl region of D2. Mol Endocrinol 17:2603-2612.
  2. Curcio-Morelli C, Zavacki AM, Christofollete M, Gereben B, de Freitas BC, Harney JW, Li Z, Wu G, Bianco AC 2003. Deubiquitination of type 2 iodothyronine deiodinase by von Hippel-Lindau protein-interacting deubiquitinating enzymes regulates thyroid hormone activation. J Clin Invest 112:189-196.
  3. Curcio-Morelli C, Gereben B, Zavacki AM, Kim BW, Huang S, Harney JW, Larsen PR, Bianco AC 2003. In vivo dimerization of types 1, 2, and 3 iodothyronine selenodeiodinases. Endocrinology 144:937-946.

1998

TOMER, Y. (1998) “Mutational and functional analysis of candidate susceptibility Genes in Graves’ disease”

  1. Ban Y, Greenberg DA, Concepcion E, Skrabanek L, Villanueva R, Tomer Y 2003. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc Natl Acad Sci U S A 100:15119-15124.
  2. Ban Y, Davies TF, Greenberg DA, Kissin A, Marder B, Murphy B, Concepcion ES, Villanueva RB, Barbesino G, Ling V, Tomer Y 2003. Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immun 4:586-593.
  3. Tomer Y, Ban Y, Concepcion E, Barbesino G, Villanueva R, Greenberg DA, Davies TF 2003. Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. Am J Hum Genet 73:736-747.
  4. Ban Y, Tomer Y 2003. The contribution of immune regulatory and thyroid specific genes to the etiology of Graves’ and Hashimoto’s diseases. Autoimmunity 36:367-379.
  5. Tomer Y, Concepcion E, Greenberg DA 2002. A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves’ disease. Thyroid 12:1129-1135.

 

MARIASH, C. (1998) “Thyroid hormone deficiency during fetal and early childhood development”

  1. Thyroid hormone regulates oligodendrocyte accumulation in developing rat brain white matter tracts. Schoonover CM, Seibel MM, Jolson DM, Stack MJ, Rahman RJ, Jones SA, Mariash CN, Anderson GW. Endocrinology. 2004 Nov;145(11):5013-20. Epub 2004 Jul 15.
  2. Campbell MC, Anderson GW, Mariash CN 2003. Human spot 14 glucose and thyroid hormone response: A characterization and thyroid hormone response element identification. Endocrinology 144:5242-5248.
  3. Ota Y, Mariash CN 2003. Paradoxical triiodothyronine suppression of S14 transcription in permanent hepatic cell lines. Thyroid 13:437-445.
  4. Jones SA, Jolson DM, Cuta KK, Mariash CN, Anderson GW 2003. Triiodothyronine is a survival factor for developing oligodendrocytes. Mol Cell Endocrinol 199:49-60.
  5. Zhu XG, Park KS, Kaneshige M, Bhat MK, Zhu Q, Mariash CN, McPhie P, Cheng SY 2000. The orphan nuclear receptor Ear-2 is a negative coregulator for thyroid hormone nuclear receptor function. Mol Cell Biol 20:2604-2618.
  6. Liu B, Li W, Mariash CN. 1999. Two different gene elements are required for glucose regulation of S14 transcription. Mol Cell Endocrinol. 148:11-19.
  7. Anderson GW, Larson RJ, Oas DR, Sandhofer CR, Schwartz HL, Mariash CN, Oppenheimer JH. 1998 Chicken ovalbumin upstream promoter-transcription factor (COUP-TF) modulates expression of the Purkinje cell protein-2 gene. A potential role for COUP-TF in repressing premature thyroid hormone action in the developing brain. 1998 J Biol Chem. 273:16391-16399.
  8. Purkinje cell protein-2 cis-elements mediate repression of T3-dependent transcriptional activation. Anderson GW, Hagen SG, Larson RJ, Strait KA, Schwartz HL, Mariash CN, Oppenheimer JH. Mol Cell Endocrinol. 1997 Jul 4;131(1):79-87.

 

WOODMANSEE, W. (1998) “Thyroid hormone regulation of mouse somatostatin 5 receptor promoter”

  1. Gordon DF, Woodmansee WW, Black JN, Dowding JM, Bendrick-Peart J, Wood WM, Ridgway EC 2002. Domains of Pit-1 required for transcriptional synergy with GATA-2 on the TSH beta gene. Mol Cell Endocrinol 196:53-66.
  2. Woodmansee WW, Mouser RL, Gordon DF, Dowding JM, Wood WM, Ridgway EC 2002. Mutational analysis of the mouse somatostatin receptor type 5 gene promoter. Endocrinology 143:2268-2276.
  3. Wood WM, Sarapura VD, Dowding JM, Woodmansee WW, Haakinson DJ, Gordon DF, Ridgway EC 2002. Early gene expression changes preceding thyroid hormone-induced involution of a thyrotrope tumor. Endocrinology 143:347-359.

 

KIM, S.-W. (1998) “Exploring the mechanism of thyroid hormone dependent gene regulation”

  1. de Jesus LA, Carvalho SD, Ribeiro MO, Schneider M, Kim SW, Harney JW, Larsen PR, Bianco AC. 2001. The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. J Clin Invest. 2001. 108:1379-1385.
  2. Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW, Rudas P, Larsen PR. 2000. Characterization of the 5′-flanking and 5′-untranslated regions of the cyclic adenosine 3′,5′-monophosphate-responsive human type 2 iodothyronine deiodinase gene. Endocrinology. 2000. 141:229-237.
  3. Kim SW, Harney JW, Larsen PR 1998. Studies of the hormonal regulation of type 2 5′-iodothyronine deiodinase messenger ribonucleic acid in pituitary tumor cells using semiquantitative reverse transcription- polymerase chain reaction. Endocrinology 139:4895-4905.

 

BIESIADA, E. (1998) “Molecular mechanisms for thyroid hormone regulation of motor neuronal process growth”

  1. Gianino S, Stein SA, Li H, Lu X, Biesiada E, Ulas J, Xu XM. 1999. Postnatal growth of corticospinal axons in the spinal cord of developing mice. Brain Res Dev Brain Res 112:189-204.

1997

BURMEISTER, L. (1997) “Thyroid hormone dependent modulation of brain function: A PET Study”

  1. Saeed, Omar, Bernstein, Lori J., Fazelzad, Rouhi, Samuels, Mary, Burmeister, Lynn A., Thabane, Lehana, Ezzat, Shereen, Goldstein, David P., Jones, Jennifer, Sawka, Anna M. Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis. Journal of Cancer Survivorship 2019
  2. Cook, Sarah E. Nebes, Robert D. Halligan, Edythe M. Burmeister, Lynn A. Saxton, Judith A. Ganguli, Mary Fukui, Melanie B. Meltzer, Carolyn C. Williams, Robert L. DeKosky, Steven T. Aging, Memory Impairment in Elderly Individuals With a Mildly Elevated Serum TSH: The Role of Processing Resources, Depression and Cerebrovascular Disease. Neuropsychology, and Cognition 2002; 9 (3): 175-183
  3. Burmeister LA, Ganguli M, Dodge HH, Toczek T, DeKosky ST, Nebes RD 2001. Hypothyroidism and cognition: preliminary evidence for a specific defect in memory. Thyroid 11:1177-1185.
  4. Lee E, Chen P, Rao H, Lee J, Burmeister LA 1999. Effect of acute high dose dobutamine administration on serum thyrotrophin (TSH). Clin Endocrinol (Oxf) 50:487-492.
  5. Zou L, Burmeister LA, Styren SD, Kochanek PM, DeKosky ST 1998. Up-regulation of type 2 iodothyronine deiodinase mRNA in reactive astrocytes following traumatic brain injury in the rat. J Neurochem 71:887-890.
  6. Burmeister LA, Pachucki J, St Germain DL 1997. Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and posttranslational mechanisms. Endocrinology

 

KOIBUCHI, N. (1997) “Thyroid hormone receptor and RORalpha action on neurotrophin gene expression in the developing cerebellum”

  1. Amano I, Takatsuru Y, Aghnia Khairinisa M, Kokubo M, Haijima A, Koibuchi N. 2018 Effects of perinatal mild hypothyroidism on learning and memory function of adult male offspring. Endocrinology 159: 1910-1921.
  2. Ariyani W, Iwasaki T, Miyazaki W, Yu L, Takeda S, Koibuchi N. 2018 Genistein and daidzein affect the thyroid hormone receptor (TR)-mediated transcription through direct binding to TR in vitro. Toxicol Sci 164:417-427.
  3. Khairinisa MA, Takatsuru Y, Amano I, Kokubo M, Haijima A, Miyazaki W, Koibuchi N. 2018 In utero and postnatal propylthiouracil-Induced mild hypothyroidism impairs maternal behavior in mice. Front Endocrinol 9:228.
  4. Amano I, Takatsuru Y, Toya S, Haijima A, Iwasaki T, Grasberger H, Refetoff S, Koibuchi N. Aberrant cerebellar development in mice lacking dual oxidase maturation factors. Thyroid 26: 741-752.
  5. Ariyani W, Iwasaki T, Miyazaki W, Khongorzul E, Nakajima T, Kameo S, Koyama H, Tsushima Y, Koibuchi N. Effects of gadolinium-based contrast agents on thyroid hormone receptor action and thyroid hormone-induced cerebellar Purkinje cell morphogenesis. Front Endocrinol 7:115.
  6. Lesmana R, Iwasaki T, Iizuka Y, Amano I, Shimokawa N, Koibuchi N. The change in thyroid hormone signaling by altered training intensity in male rat skeletal muscle. Endocrine J 63: 727-738.
  7. Yu L, Iwasaki T, Xu M, Lesmana R, Xiong Y, Shimokawa N, Chin WW, Koibuchi N. 2015 Aberrant cerebellar development of transgenic mice expressing dominant-negative thyroid hormone receptor in cerebellar Purkinje cells. Endocrinology 156: 1565-1576.
  8. Shimokawa N, Yousefi B, Morioka S, Yamaguchi S, Ohsawa A, Hayashi H, Azuma A, Mizuno H, Kasagi M, Masuda H, Jingu H, Furudate SI, Haijima A, Takatsuru Y, Iwasaki T, Umezu M, Koibuchi N. 2014 Altered cerebellum development and dopamine distribution in a rat genetic model with congenital hypothyroidism. J Neuroendocrinol 26: 164-175.
  9. Xu M, Iwasaki T, Shimokawa N, Sajdel-Sulkowska EM, Koibuchi N. The effect of low dose lipopolysaccharide on thyroid hormone-regulated actin cytoskeleton modulation and type 2 Iodothyronine deiodinase activity in astrocytes. Endocrine J 60: 1221-1230
  10. Xiong Y, Ibhazehiebo K, Iwasaki T, Koibuchi N. An in vitro method to study the effects of thyroid hormone-disrupting chemicals on neuronal development. Neurotoxicology 33: 753-757.
  11. Ibhazehiebo K, Iwasaki T, Okano-Uchida T, Shimokawa N, Ishizaki Y, Koibuchi N. Suppression of thyroid hormone receptor-mediated transcription and disruption of thyroid hormone-induced cerebellar morphogenesis by the polybrominated biphenyl mixture, BP-6.  Neurotoxicology 32: 400-409.
  12. Ibhazehiebo K, Iwasaki T, Xu M, Shimokawa N, Koibuchi N. Brain-derived neurotrophic factor (BDNF) ameliorates the suppression of thyroid hormone-induced granule cell neurite extension by hexabromocyclododecane (HBCD). Neurosci Lett　493: 1-7.
  13. Ibhazehiebo K, Iwasaki T, Shimokawa N, Koibuchi N. 　1,2,5,6,9,10-α Hexabromocyclododecane (HBCD) impairs thyroid hormone-induced dendrite arborization of Purkinje cells and suppresses thyroid hormone receptor-mediated transcription. Cerebellum10: 22-31.
  14. Ibhazehiebo K, Iwasaki T, Kimura-Kuroda J, Miyazaki W, Shimokawa N, Koibuchi N. Disruption of thyroid hormone receptor-mediated transcription and thyroid hormone-induced Purkinje cell dendrite arborization by polybrominated diphenyl ethers. Env Health Perspect 119: 168-175.
  15. Amano I, Miyazaki W, Iwasaki T, Shimokawa N, Koibuchi N. The effect of hydroxylated polychlorinated biphenyl (OH-PCB) on thyroid hormone receptor (TR)- mediated transcription through native-thyroid hormone response element (TRE). Industrial Health 48: 115-118.
  16. Qiu CH, Miyazaki W, Iwasaki T, Londoño M, Ibhazehiebo K, Shimokawa N, Koibuchi N. Retinoic acid receptor-related orphan receptor alpha-enhanced thyroid hormone receptor-mediated transcription requires its ligand binding domain which is not, by itself, sufficient: possible direct interaction of two receptors. Thyroid 19: 893-898.
  17. Miyazaki W, Iwasaki T, Takeshita A, Tohyama C, Koibuchi N.   Identification of the functional domain of thyroid hormone receptor responsible for polychlorinated biphenyl-mediated suppression of its action in vitro.  Environ Health Perspect 116: 1231-1236.
  18. Qiu CH, Shimokawa N, Iwasaki T, Parhar IS, Koibuchi N. Alteration of cerebellar neurotropin messenger ribonucleic acids and the lack of thyroid hormone receptor augmentation by staggerer- type retinoic acid receptor-related orphan receptor-a mutation. Endocrinology 148: 1745-1753.
  19. Iwasaki T, Takeshita A, Miyazaki W, Chin WW, Koibuchi N. 2006. The interaction of TRb1-N terminus with steroid receptor coactivator -1 (SRC-1) serves a full transcriptional activation function of SRC-1. Endocrinology 147: 1452-1457.
  20. Yousefi B, Jingu H, Ohta M, Umezu M, Koibuchi N. 2005. Postnatal changes of steroid receptor coactivator-1 immunoreactivity in rat cerebellar cortex. Thyroid 15: 314-319.
  21. Vasudevan N, Kia HK, Hadjimarkou M, Koibuchi N, Chin WW, Forrest D, Vennstrom B, Pfaff D. 2005. Retinoid-related receptor (ROR)a mRNA expression is altered in the brain of male mice lacking all ligand-binding thyroid hormone receptor (TR) isoforms. Endocrine 26: 25-32.
  22. Iwasaki T, Koibuchi N, Chin WW. 2005. Synovial sarcoma translocation (SYT) encodes a nuclear receptor coactivator. Endocrinology 146: 3892-3899.
  23. Miyazaki W, Iwasaki T, Takeshita A, Kuroda Y, Koibuchi N  Polychlorinated biphenyls (PCBs) suppress thyroid hormone (TH) receptor (TR)-mediated transcription through a novel mechanism. J Biol Chem (In press)
  24. Vasudevan N, Koibuchi N, Chin WW, Pfaff DW 2001. Differential crosstalk between estrogen receptor (ER)alpha and ERbeta and the thyroid hormone receptor isoforms results in flexible regulation of the consensus ERE. Brain Res Mol Brain Res 95:9-17.
  25. Kia HK, Krebs CJ, Koibuchi N, Chin WW, Pfaff DW 2001. Co-expression of estrogen and thyroid hormone receptors in individual hypothalamic neurons. J Comp Neurol 437:286-295.
  26. Koibuchi N, Yamaoka S, Chin WW 2001. Effect of altered thyroid status on neurotrophin gene expression during postnatal development of the mouse cerebellum. Thyroid 11:205-210.
  27. Martinez dA, Koibuchi N, Chin WW 2000. Coactivator and corepressor gene expression in rat cerebellum during postnatal development and the effect of altered thyroid status. Endocrinology 141:1693-1698.
  28. Koibuchi N, Fukuda H, Chin WW 1999. Promoter-specific regulation of the brain-derived neurotropic factor gene by thyroid hormone in the developing rat cerebellum. Endocrinology 140:3955-3961.
  29. Koibuchi N, Liu Y, Fukuda H, Takeshita A, Yen PM, Chin WW 1999. ROR alpha augments thyroid hormone receptor-mediated transcriptional activation. Endocrinology 140:1356-1364.

 

LEE, S.L. (1997) “Novel and multi-disciplinary approach to understanding the physiological regulation by thyroid hormone of the TRH neurones in the paraventricular nucleus of the hypothalamus”

  1. Fragner P, Lee SL, Aratan dL 2001. Differential regulation of the TRH gene promoter by triiodothyronine and dexamethasone in pancreatic islets. J Endocrinol 170:91-98.
  2. Luo LG, Lee SL, Lechan RM, Jackson IM 2001. Effect of preproTRH antisense on thyrotropin-releasing hormone synthesis and viability of cultured rat diencephalic neurons. Endocrine 15:79-85.

 

PUYMIRAT, J. (1997) “Physiopathology of brain dysfunctions in congenital hypothyroidism”– 19 citations

  1. Martel J, Cayrou C, Puymirat J 2002. Identification of new thyroid hormone-regulated genes in rat brain neuronal cultures. Neuroreport 13:1849-1851.
  2. Cayrou C, Denver RJ, Puymirat J 2002. Suppression of the basic transcription element-binding protein in brain neuronal cultures inhibits thyroid hormone-induced neurite branching. Endocrinology 143:2242-2249.
  3. Baas D, Puymirat J, Sarlieve LL 1998. Posttranscriptional regulation of oligodendroglial thyroid hormone (T3) receptor beta 1 by T3. Int J Dev Neurosci 16:461-467.
  4. Nobrega JN, Raymond R, Puymirat J, Belej T, Joffe RT 1997. Regional changes in beta1 thyroid hormone receptor immunoreactivity in rat brain after thyroidectomy. Brain Res 761:161-164.

1996

HAUSER, P. (1996) “A quantitative study of brain structures in subjects with resistance to thyroid hormone”

  1. Phillips SA, Rotman-Pikielny P, Lazar J, Ando S, Hauser P, Skarulis MC, Brucker-Davis F, Yen PM 2001. Extreme thyroid hormone resistance in a patient with a novel truncated TR mutant. J Clin Endocrinol Metab.
  2. Hauser P, McMillin JM, Bhatara VS 1998. Resistance to thyroid hormone: implications for neurodevelopmental research on the effects of thyroid hormone disruptors. Toxicol Ind Health 14:85-101.
  3. Hauser P, Soler R, Brucker-Davis F, Weintraub BD 1997. Thyroid hormones correlate with symptoms of hyperactivity but not inattention in attention deficit hyperactivity disorder. Psychoneuroendocrinology 22:107-114.

 

ROVET, J. (1996) “Early sequel of abnormal intrauterine and postnatal thyroid hormone exposure”

  1. Lischinsky, J., Skockic, J., Clairman, H., Rovet, J.F. Maternal hypothyroidism is associated with abnormal cortical morphology in the offspring. (Front Endocrinol (Lausanne). 2016 Feb 25;7:16. doi: 10.3389/fendo.2016.00016. eCollection 2016. PMID: 26941710
  2. Samedi A., Skocic J., Rovet, J.F. Children born to women with hypothyroidism during pregnancy show abnormal corpus callosum development. Thyroid 25:494-502. doi: 10.1089/thy.2014.0548. Epub 2015 Apr 7. PubMed PMID: 25780811.
  3. Rovet, J.F. The role of thyroid hormones for brain development and cognitive function. Endocr Dev 2014 26:26-43 doi: 10.1159/000363153. Epub 2014 Aug 29. PubMed PMID: 25231442.
  4. Willoughby, K.N., McAndrews, M.P., Rovet, J.F. Accuracy of episodic autobiographical memory in children with early thyroid hormone deficiency using a staged event. Developmental Cognitive Neuroscience 2014 9:1-11. doi:10.1016/j.dcn.2013.12.005
  5. Willoughby, K.A., McAndrews, M.P., & Rovet, J.F. Effects of early thyroid hormone deficiency on children’s autobiographical memory performance. Journal of the International Neuropsychological Society 2013:19:419-429.
  6. Gilbert, M.E., Rovet, J.F., Chen, Z.P., Koibuchi, N. Developmental thyroid hormone disruption: Prevalence, environmental contaminants and neurodevelopmental consequences. Neurotoxicology 2012:33(4):842-852.
  7. Vaidya, B., Negro, R., Poppe, K., Rovet, J.F. Thyroid and pregnancy. Journal of Thyroid Research 2011:Article ID 680328:3 pages. doi:10.4061/2011/680328
  8. Rovet, J.F. & Willoughby, K.A. (2010). Maternal thyroid function and fetal brain development. In A. Zimmerman & S. Connors (Eds.), Maternal influences on fetal neurodevelopment: Clinical and research aspects. New York, NY: Springer.
  9. Willoughby, K.A., Sheard, E.D., I, K., Rovet, J.F. Effects of prenatal alcohol exposure on hippocampal volume, verbal learning, and spatial memory. Journal of the International Neurological Society 2008:14:1022-1033
  10. Mirabella, G., Westall, C., Asztalos, E., Perlman, K., Koren, G., Rovet, J.F. The development of contrast sensitivity in infants with prenatal and neonatal thyroid hormone insufficiencies.  Pediatrics Research 2005:57(6):902-907
  11. Zoeller, T., Rovet, J.F. Timing of thyroid hormone action in the developing brain: Clinical observations and experimental findings. Journal of Neuroendocrinology 2004:16:809-818.
  12. Zoeller RT, Bigelow C, Rovet J 2004. Lack of a relation between human neonatal thyroxine and pediatric neurobehavioral disorders: neonatal total thyroxine is not a good proxy measure of maternal thyroid hormone insufficiency. Thyroid 14:239-241.
  13. Rovet J 2003. Long-term follow-up of children born with sporadic congenital hypothyroidism. Ann Endocrinol
  14. Till C, Koren G, Rovet JF 2002. Agreement between prospective and retrospective reports of maternal exposure to chemicals during pregnancy. J Occup Environ Med 44:708-713.
  15. Song SI, Daneman D, Rovet J 2001. The influence of etiology and treatment factors on intellectual outcome in congenital hypothyroidism. J Dev Behav Pediatr 22:376-384.
  16. Mirabella G, Feig D, Astzalos E, Perlman K, Rovet JF 2000. The effect of abnormal intrauterine thyroid hormone economies on infant cognitive abilities. J Pediatr Endocrinol Metab 13:191-194.
  17. Magee LA, Nulman I, Rovet JF, Koren G 1999. Neurodevelopment after in utero amiodarone exposure. Neurotoxicol Teratol 21:261-265.

 

PAVLIDES, C. (1996) “Developmental changes in hippocampal physiology and synaptic plasticity: Effects of altered thyroid state during the perinatal period”

  1. Caria, M. A., Dratman, M. B., Kow, L.-M., Mameli, O. & Pavlides, C. Thyroid hormone action: nongenomic modulation of neuronal excitability in the hippocampus. J Neuroendocrinol 21, 98–107 (2009)
  2. Yamada K, McEwen BS, Pavlides C 2003. Site and time dependent effects of acute stress on hippocampal long-term potentiation in freely behaving rats. Exp Brain Res 152:52-59.
  3. Ribeiro S, Mello CV, Velho T, Gardner TJ, Jarvis ED, Pavlides C 2002. Induction of hippocampal long-term potentiation during waking leads to increased extrahippocampal zif-268 expression during ensuing rapid-eye- movement sleep. J Neurosci 22:10914-10923.
  4. Pavlides C, Nivon LG, McEwen BS 2002. Effects of chronic stress on hippocampal long-term potentiation. Hippocampus 12:245-257.
  5. Pavlides, C., Westlind-Danielsson, A. I., Nyborg, H. & McEwen, B. S. Neonatal hyperthyroidism disrupts hippocampal LTP and spatial learning. Exp Brain Res 85, 559–564 (1991)
  6. Sarnyai Z, Sibille EL, Pavlides C, Fenster RJ, McEwen BS, Toth M 2000. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc Natl Acad Sci U S A 97:14731-14736.
  7. Pavlides C, McEwen BS 1999. Effects of mineralocorticoid and glucocorticoid receptors on long-term potentiation in the CA3 hippocampal field. Brain Res 851:204-214.
  8. Jellinck PH, Pavlides C, Sakai RR, McEwen BS 1999. 11beta-hydroxysteroid dehydrogenase functions reversibly as an oxidoreductase in the rat hippocampus in vivo. J Steroid Biochem Mol Biol 71:139-144.
  9. Ribeiro S, Goyal V, Mello CV, Pavlides C 1999. Brain gene expression during REM sleep depends on prior waking experience. Learn Mem 6:500-508.